Impact of baseline, trend, and normalization of carcinoembryonic antigen on survival in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Yu-MU Chen

Citation

Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532

Authors

Y. Chen1, C. Lai2, M. Lin3

Author affiliations

  • 1 Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung, 833 - Kaohsiung/TW
  • 2 Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung/TW
  • 3 Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung/TW
More

Resources

Aim/Background

Non-small cell lung cancer (NSCLC) patients with higher carcinoembryonic antigen (CEA) levels tend to have mutant epidermal growth factor receptor (EGFR). Thus, in patients with unknown EGFR mutation status, those with higher CEA are more likely to response to EGFR-tyrosine kinase inhibitors (TKIs). However, patients with higher CEA also have more tumor burden. With the above paradoxical evidence, it is prudent to understand the prognostic significance of baseline CEA in patients with EGFR-mutant NSCLC treated with first-line EGFR-TKIs. The clinical significance of the trend in CEA after treatment and the impact of CEA normalization during EGFR-TKI therapy are also unknown and potentially important.

Methods

241 patients who received first-line EGFR-TKIs were included. Patients were divided into 3 groups accordingly to their CEA response. In group A, 1-month follow-up CEA level decreased more than 35% with nadir CEA normalization; in group B, 1-month follow-up CEA level decreased more than 35% without nadir CEA normalization; in group C, 1-month follow-up CEA level decreased less than 35% or increased.

Results

Patients with lower baseline CEA levels had longer overall survival (OS) duration (CEA > 32 vs. 5-32 vs. < 32 ng/mL, OS = 17.8 vs. 22.0 vs. 27.9 months, respectively; p = 0.014). For trend and nadir CEA levels, OS duration was 29.7, 20.0, and 16.2 months in groups A, B, and C, respectively (p < 0.001).

Conclusions

CEA are potential prognostic markers for patients with EGFR-mutant NSCLC treated with first line EGFR-TKIs.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings